Inovio Pharmaceuticals Inc (NASDAQ:INO) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.65.
INO has been the topic of several analyst reports. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 16th. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 26th. ValuEngine raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 10th. Finally, Maxim Group set a $8.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 26th.
In other Inovio Pharmaceuticals news, CFO Peter Kies sold 10,001 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $5.28, for a total transaction of $52,805.28. Following the transaction, the chief financial officer now owns 72,089 shares of the company’s stock, valued at $380,629.92. The sale was disclosed in a document filed with the SEC, which is available through this link. 9.40% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of Inovio Pharmaceuticals by 8.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,837 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 2,233 shares during the last quarter. Quantamental Technologies LLC acquired a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $43,000. Meeder Asset Management Inc. grew its position in shares of Inovio Pharmaceuticals by 522.6% in the fourth quarter. Meeder Asset Management Inc. now owns 14,718 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 12,354 shares during the last quarter. Pembroke Management LTD acquired a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $52,000. Finally, Emerald Advisers Inc. PA grew its position in shares of Inovio Pharmaceuticals by 24.3% in the third quarter. Emerald Advisers Inc. PA now owns 72,125 shares of the biopharmaceutical company’s stock valued at $401,000 after purchasing an additional 14,080 shares during the last quarter. 34.10% of the stock is currently owned by institutional investors.
INO traded down $0.01 on Tuesday, hitting $4.67. 6,702 shares of the company were exchanged, compared to its average volume of 696,568. Inovio Pharmaceuticals has a 12 month low of $3.64 and a 12 month high of $6.30. The firm has a market capitalization of $439.56 million, a PE ratio of -4.31 and a beta of 1.96.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. Inovio Pharmaceuticals had a negative return on equity of 72.66% and a negative net margin of 232.58%. The business had revenue of $2.00 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter in the prior year, the company posted ($0.39) earnings per share. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -1 earnings per share for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: Beta
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.